These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 32582979)
1. Age‑related changes in mineralocorticoid receptors in rat hearts. Hu D; Dong R; Zhang Y; Yang Y; Chen Z; Tang Y; Fu M; Xu X; Tu L Mol Med Rep; 2020 Sep; 22(3):1859-1867. PubMed ID: 32582979 [TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996 [TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism. Wang M; Li Y; Zhou K; Zhang G; Wang Y; Liu T; Zhang Y; Guo A; An Y Cell Physiol Biochem; 2016; 39(3):860-70. PubMed ID: 27497962 [TBL] [Abstract][Full Text] [Related]
4. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023 [TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Whaley-Connell A; Habibi J; Wei Y; Gutweiler A; Jellison J; Wiedmeyer CE; Ferrario CM; Sowers JR Am J Physiol Renal Physiol; 2009 May; 296(5):F1013-22. PubMed ID: 19261739 [TBL] [Abstract][Full Text] [Related]
6. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Lother A; Bergemann S; Kowalski J; Huck M; Gilsbach R; Bode C; Hein L Cardiovasc Res; 2018 Feb; 114(2):282-290. PubMed ID: 28430882 [TBL] [Abstract][Full Text] [Related]
8. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451 [TBL] [Abstract][Full Text] [Related]
17. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Messaoudi S; Gravez B; Tarjus A; Pelloux V; Ouvrard-Pascaud A; Delcayre C; Samuel J; Launay JM; Sierra-Ramos C; Alvarez de la Rosa D; Clément K; Farman N; Jaisser F Hypertension; 2013 Feb; 61(2):361-7. PubMed ID: 23297371 [TBL] [Abstract][Full Text] [Related]
18. A combined CaMKII inhibition and mineralocorticoid receptor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice. Driessen HE; Fontes MS; van Stuijvenberg L; Brans MA; Goumans MJ; Vos MA; van Veen TA J Cell Mol Med; 2020 Aug; 24(15):8417-8429. PubMed ID: 32573944 [TBL] [Abstract][Full Text] [Related]
19. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434 [TBL] [Abstract][Full Text] [Related]